Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.130.03%
QQQ
709.610.06%
BTC/USD
77868.000.4147%
DIA
524.660.03%
GLD
393.070.06%
TLT
80.93-

Taysha Gene Therapies Inc

TSHANASDAQ
Trade with Public
Trade with Public
$5.01
-0.01-0.2%
At close: Sep 14, 5:00 PM EST
$5.10
0.091.8%
After Hours: 7:16 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Taysha Gene Therapies Analyst Price Targets

Wall Street analyst price targets and consensus rating for Taysha Gene Therapies (TSHA).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

3S.Buy
12Buy
Consensus RatingBuy# Analysts15Avg. Consensus PT$11Upside to Avg. PT+110.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 21, 2026Goldman SachsSalveen RichterPT RaiseBuy$11→$13
Jul 2, 2026CitizensSilvan TurkcanMaintainedMarket Outperform$11
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13

Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $11 to $13.
Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target

Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and maintains $11 price target.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15

Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $12 to $15.
Benzinga Newsdesk

PRO
BMO Capital Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $14

BMO Capital analyst Keith Tapper maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $10 to $14.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10

B of A Securities analyst Tazeen Ahmad maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $9 to $10.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Taysha Gene Therapies, Raises Price Target to $11

Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and raises the price target from $8 to $11.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved